Drug Profile
Aganirsen - Gene Signal
Alternative Names: Antisense oligonucleotide TATCCGGAGGGCTCGCCATGCTGCT; GS-101; TATCCGGAGGGCTCGCCATGCTGCTLatest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Gene Signal
- Class Antiglaucomas; Antineoplastics; Antipsoriatics; Antisense oligonucleotides; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action Insulin receptor substrate protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Keratoplasty rejection; Psoriasis; Retinopathy of prematurity; Rosacea
Highest Development Phases
- Phase III Keratoplasty rejection
- Phase II Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
- Phase I Bladder cancer
- Discontinued Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Psoriasis; Retinopathy of prematurity; Rosacea
Most Recent Events
- 26 Apr 2022 Aganirsen is still in phase-II trials for Diabetic macular oedema in France (Topical) (Gene Signal pipeline, April 2022)
- 26 Apr 2022 Aganirsen is still in phase-II trials for Wet age-related macular degeneration in France (Topical) (Gene Signal pipeline, April 2022)
- 03 Jan 2020 Discontinued - Phase-I for Diabetic retinopathy in France (Topical) (Gene Signal pipeline, January 2020)